Zevra Therapeutics (ZVRA) Non-cash Items (2014 - 2024)

Zevra Therapeutics has reported Non-cash Items for 11 years, with the latest figure at $17.4 million in Q4 2024.

• For the quarter ending Q4 2024, Non-cash Items rose 57.35% year-over-year to $17.4 million; the trailing twelve-month figure through Dec 2024 stood at $17.4 million (up 57.35% YoY), and the FY2024 full-year result was $17.4 million, up 624.54% from the prior year.
• Non-cash Items for Q4 2024 stood at $17.4 million, up from $11.1 million in the prior quarter.
• The five-year high for Non-cash Items was $17.4 million in Q4 2024, with the low at $254207.0 in Q4 2021.
• Historically, Non-cash Items has averaged $8.2 million across 5 years, with a median of $11.1 million in 2023.
• Annual changes were most pronounced in 2020 — Non-cash Items tumbled 74.8% — and 2022, when it jumped 4549.36%.
• Zevra Therapeutics' Non-cash Items stood at $543021.0 in 2020, then sank by 53.19% to $254207.0 in 2021, then jumped by 4549.36% to $11.8 million in 2022, then retreated by 6.18% to $11.1 million in 2023, then surged by 57.35% to $17.4 million in 2024.
• The last three Non-cash Items figures came in at $17.4 million (Q4 2024), $11.1 million (Q4 2023), and $11.8 million (Q4 2022), per Business Quant data.